New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country.
The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and Oxford University.
In in its application to the the Drug Controller General of India (DCGI), SII cited “unmet medical needs due to the pandemic and in the interest of the public at large” as the reason for seeking emergency authorisation of the vaccine emergency use approval.
Earlier, Pfizer India became the first pharmaceutical firm to seek emergency use authorisation for its COVID-19 vaccine candidate in the country.
Bargarh: A new artist will be selected to play the mythological character King Kansa during…
Mumbai: Suhana Khan will be making her Bollywood debut with ‘King’ along with her superstar…
New Delhi: After Diljit Dosanjh called out the double standards of Telangana government for banning…
New Delhi: Recent actions and counter-actions in the Russia-Ukraine conflict have pushed the world to the…
Balangir: Three persons were arrested and fake IPS officers’ uniforms along with fake identity cards…
Mumbai: Abhishek Bachchan’s highly-anticipated film ‘I Want To Talk’ released in theatres on Friday, and the…
New Delhi: Accused of giving cash to secure votes ahead of election day in Maharashtra,…
Bhubaneswar: Chief Minister Mohan Charan Majhi attended the ‘Odisha State Day Celebrations’ at the 43rd…